PRECISION AI SOLUTIONS

Find the best drug for each cancer patient

Summary Pitch Deck
2025

Executive Summary

Unlocking precision oncology for the 92% left behind.

Problem

In 2024, over 2 million Americans will be diagnosed with cancer, many facing limited treatment options. Despite advances in precision oncology, **92% of cancer patients receive little actionable guidance from current biomarker tests**.

Solution

We're transforming cancer care with an AI ecosystem that guides oncologists through treatment options. Our platform ranks therapies **using real-world gene network analysis, beyond biomarker limitations**.

Market

Targeting unmet need in a $50B+ Precision Oncology Market. We're **raising a $5M seed round**—including $1M in SAFE notes for angel investors—to expand clinical validation and strategic partnerships—Series A ($20M) to scale.

The Problem

Precision Oncology Isn't Reaching Most Patient

What Doctors Face Today:

- 240+ approved cancer drugs
- Only 30–45% of patients have a biomarker match
- Only 25–46% benefit from matched therapy

Result: Trial-and-error decisions, delays, wasted cost, poor outcomes

Pancreatic cancer exemplifies this, with a 90%+ mortality rate and few effective therapies.



Our Solution

A GPS for oncologists in the fog of cancer complexity

Oncology CoPilot bridges the gap when biomarkers are absent or fail, helping oncologists make smarter treatment decisions from **day 1**.

- Analyzes RNA from each patient's tumor — 20,000 genes
- Integrates:
  a. Curated oncology knowledge
  b. Immune profiles & tumor biology
  c. Drug databases
- Powered by AI trained on ~150 biological features representing gene groups & pathways



Real-world Data



Gene network analysis



AI Model

Why Oncology CoPilot Stands Apart

Beyond Mutations and reach the 92% left behind

Current solutions stop at DNA. Players like Foundation Medicine and Tempus rely on known biomarkers—but when no clear mutation is present, they're stuck.

- Oncology CoPilot goes further. We use RNA sequencing and AI to analyze real-time tumor behavior—revealing active pathways, immune response, and cancer drivers.

- Broader Reach: Delivers insights for more patients—including those without actionable mutations, with complex profiles, or resistant to standard treatments.

We're not replacing doctors — we're equipping them.
We're not discarding biomarkers — we're building on them.

Product Overview (IP Protected)



Proof of Concept & Clinical Validation

Real-World Results:

- ~76% improvement in drug efficacy in POC study
- Trained and tested on real-world patient datasets—not just simulated models

Work in Progress:

- Real-world evidence retrospective studies to validate results and accuracy
- Pilot studies on validating drug efficacy for breast cancer in African Americans
- Exploration of clinical trial to validate clinical impact

Why It Matters:

- Builds confidence in clinical utility and generalizability
- Supports regulatory pathways that value real-world evidence over RCTs
- Positions Oncology CoPilot for broader clinical adoption and reimbursement

Market Opportunity

The fragmented oncology precision medicine market is expected to grow to $125B in 2030.

TAM: $50B
Global Precision Oncology Market

SAM: $5B+
NGS Oncology Testing (doubling soon) with RNA-seq adoption is accelerating.



SOM: $250–500M
2M new cancer cases/year in U.S.
Growing RNA-seq and CDS adoption

Target Users:
Oncologists, tumor boards, cancer centers, research networks

Competitive Landscape

RNA-seq unlocks insights beyond biomarkers, which are focused on specific cancers and unscalable.

Company	Stage	Funding	Target Cancers	Drugs
Precision AI Solutions	**Seed**	**-**	**2, scalable to All**	**All classes**
Pangea Biomed	Seed	$12M	11	Targeted/ Immunotherapy
OncXerna Therapeutics	Series C	$126M	7	6
Tempus AI	Public - TEM	-	With known biomarkers	Biomarker targeted
Foundation Medicine	Public - FMI	-	With known biomarkers	Biomarker targeted
Guardant Health	Public - GH	-	With known biomarkers	Biomarker targeted

Competitive Advantage

What We Understand That Others Don't

- Precision oncology is not just about mutations—it's about biological system.
- RNA reveals dynamic tumor biology that DNA can't.
- Transcriptomics is the next frontier—we're already there.

Barriers to entry:

- Proprietary model trained on real-world RNA-seq data
- Real-world datasets, not synthetic simulations
- 150+ interpretable gene group features
- Deep partnerships with researchers, oncologists + VA

Customer Segments

Oncologists

Partner with oncologists/hospital & clinics on a limited trial basis

Clinical trials

For higher success in clinical trials and better patient outcome

Phase 1 (2025)

Pharmaceuticals & Biotechs

For accelerated drug/biomarker development

Diagnostic labs

Partner with NGS testing labs to provide value-added report

Phase 2 (2026)

Entry Point

Focusing on high mortality cancers and stages with the least clinical resistance due to lack of alternatives.

- Pancreatic is one of the deadliest cancers
  - Few treatment options
  - Limited Biomarkers
  - Cases 66,000; Deaths 52,000 (Est 2024)

- Prostate is the second leading cause of death in American men
  - Limited hormonal treatment options
  - No effective 2nd/3rd line treatments
  - Cases 300,000; Deaths 35,000 (Est 2024)

Early partners include independent oncologists, NGS labs, and trial sponsors needing AI-driven stratification

Current State & Future

Now (2025)

- **MVP Launched & Validation Underway**: Oncology CoPilot is live, with RWE validation and early clinical trials underway. Oncologist feedback is actively shaping performance refinement.
- **Strategic Partnerships & Data Scale-Up**: Partnered with NGS labs, organoid drug testing providers, and bio-specimen companies to enhance AI training and validation.
- **Market Readiness & Clinical Momentum:** Provisional patent filed, clinical validation in progress, and in discussions with leading cancer centers including UCSF, Stanford, OHSU, Moffitt, and the Parker Institute.

Future (2026+)

- **Platform Evolution & Tech Integration**: Evolve Oncology CoPilot to support pan-cancer applications by integrating emerging technologies such as multi-omics, spatial biology, and real-world data.
- **Next-Gen Companion Diagnostics**: Develop AI-powered companion diagnostics with a seamless sample-to-report platform to accelerate precision treatment decisions and optimize clinical trial success.
- **Global Scale-Up**: Expand certified clinical lab partnerships and AI deployment to reach 200K+ patients globally, while growing adoption among top cancer centers and pharmaceutical companies.

Roadmap

2025

- Retrospective RWE study
- Partnerships
- Provisional IP filed

2026

- Clinical trials (Pancreatic, Prostate)
- PR/Marketing
- Product Launch
- Full IP protection

2027

- Series A raise
- Commercialization
- 1000+ patients

2028

- Sample to answer platform
- Scale up certified clinical testing lab
- Pharmaceutical/biotech companies
- 5000+ patients

2029+

- Globalization
- US, Europe, Asia
- 200K+ patients

Team

Management

Edwin Alphonso, MBA
CEO

Sophia Ren, PhD
CSO

Seth Leffel, ME
CTO

Zheng Xu, BS
CPO

Advisors

Marc Shuman, MD
Emeritus Chief
UCSF Dept of Oncology

Mark Lu, MD
Professor and Vice Chair,
UCSF Dept of Laboratory Medicine

Eric Lau, PhD
Associate Director
OHSU Knight Cancer Institute

Andrew Ko, MD
Chief Medical Officer
UCSF Pancreas Center

THANKS!

Do you have any questions?

Edwin Alphonso, CEO

edwin.alphonso@precision-ai.com
+1 (510) 458 9862
www.precision-ai.com